title: Experience with cyclosporine in 1519 kidney transplantations from living donors in a national transplant programme, 1983-2002.
abstract: Following the introduction of cyclosporine as basic immunosuppression in our national transplant programme in 1983, the pool of grafts from living donors (LDs) was expanded 2 years later by also accepting LDs mismatched for 2 HLA haplotypes and living unrelated donors (LURDs), mostly spouses. A policy of approaching family members to promote donation was consistently pursued. During 1983 through 2002, nephrectomy was performed on 1519 LDs without mortality. From 1983 through 1988, our learning phase in managing cyclosporine-immunosuppression, 382 patients received first grafts from LDs. One-year graft survival (GS) rates were 94.4%, 90%, 89%, and 82% in 71 HLA identical, 260 haploidentical, 18 2-haplotypes disparate, and 33 LURD graft recipients, respectively. Corresponding half-lives were 15.8, 10.3, 11, and 9.1 years, respectively. Results improved in 1028 patients receiving first LD grafts from 1989 through 2002. Corresponding 1-year GS rates were 96.6% (n=117), 93.5% (n=650), 90.4% (n=73), and 88.8% (n=188), and half-lives were 30, 13.3, 13.5, and 12.3 years, respectively. Similar GS rates were observed in 109 recipients of repeat grafts from LDs. LDs contributed 44% and 21.6% of all first and repeat grafts transplanted, providing grafts to 11 patients (in 1983) increasing to 23 patients (in 2002) per million population per year (pmp/y). When added to grafts from cadaveric donors, 40 to 48 pmp/y were provided with a first or repeat graft since 1990, thus covering at least 65% of the national need for kidney transplantations.
authors.affiliation: Rikshospitalet, University Hospital, Oslo, Norway.
authors.forename: D
authors.initials: D
authors.lastname: Albrechtsen
authors.forename: T
authors.initials: T
authors.lastname: Leivestad
authors.forename: I
authors.initials: I
authors.lastname: Brekke
authors.forename: P
authors.initials: P
authors.lastname: Fauchald
authors.forename: P
authors.initials: P
authors.lastname: Pfeffer
authors.forename: E
authors.initials: E
authors.lastname: Thorsby
mesh_terms: D016572:Cyclosporine / Q000627:therapeutic use*; D006084:Graft Rejection / Q000453:epidemiology / Q000276:immunology; D006085:Graft Survival / Q000502:physiology; D006650:Histocompatibility Testing; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality / Q000502:physiology / Q000706:statistics & numerical data; D019520:Living Donors; D012189:Retrospective Studies; D016019:Survival Analysis; D014850:Waiting Lists
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine